CLDX

Market-moving news on Celldex Therapeutics (NASDAQ: CLDX): filings, earnings, deals and other events, from REDFILED.

CLDX

Both EMBARQ-CSU studies met primary and all key secondary endpoints, with complete response rates above 42% at week 12; BLA planned for 2027.

CLDX

Both EMBARQ-CSU studies met their primary and all key secondary endpoints, with complete response rates above 42% at 12 weeks; BLA planned for 2027.